The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin is a research paper published in Journal of Allergy and Clinical Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: AI134907
National Institutes of Health
Grant: AI145617
National Institutes of Health
Grant: HHSN272201600013C
National Institutes of Health
Grant: UL1TR001439
NIAID NIH HHS
Grant: R01 AI134907
NIAID NIH HHS
Grant: R43 AI145617
National Institutes of Health
Grant: 1R43AI145617-01A1
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats
National Institutes of Health
Grant: 3R01AI134907-03S2
A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery
National Institutes of Health
Grant: 5UL1TR001439-07
UTMB Clinical and Translational Science Award
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
John S. Dunn Foundation
Amon G. Carter Foundation
Summerfield G. Roberts Foundation
Gillson Longenbaugh Foundation
Sealy and Smith Foundation
FWCI
0.91
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals